This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, M. R. Articles by Kantoff, P. W. Search for Related Content PubMed PubMed Citation Articles by Smith, M. R. Articles by Kantoff, P. W. Social Bookmarking                            What's this?

Celecoxib Versus Placebo for Men With Prostate Cancer and a Rising Serum Prostate-Specific Antigen After Radical Prostatectomy and/or Radiation Therapy

Matthew R. Smith, Judith Manola, Donald S. Kaufman, William K. Oh, Glenn J. Bubley, Philip W. Kantoff

From the Massachusetts General Hospital; Beth Israel Deaconess Medical Center; and the Dana-Farber Cancer Institute, Boston, MA

Address reprint requests to Matthew Smith, MD, PhD, Massachusetts General Hospital Cancer Center, Yawkey 7038, 55 Fruit St, Boston MA 02114; e-mail: smith.matthew{at}mgh.harvard.edu

PURPOSE: To assess the biologic activity of celecoxib, a selective cyclooxygenase-2 inhibitor, in men with recurrent prostate cancer using change in prostate-specific antigen (PSA) doubling time (PSADT) as the primary outcome variable.

PATIENTS AND METHODS: Participants had histologically confirmed prostate cancer, no recent hormone therapy, rising serum PSA after radical prostatectomy and/or radiation therapy, and no radiographic evidence of metastases. Patients were randomly assigned to celecoxib (400 mg by mouth twice daily) or placebo. Treatment continued until disease progression or until adverse effects stopped treatment. A positive outcome was defined as post-treatment PSADT of more than 200% baseline PSADT with no new metastases.

RESULTS: The study was terminated early after information about the cardiovascular safety of celecoxib prompted review of ongoing clinical studies. Before discontinuation of the study, 78 men were assigned randomly to either celecoxib or placebo. Eight (20%) of 40 men in the placebo group and 15 (40%) of 38 men in the celecoxib group had post-treatment PSADT of more than 200% of baseline PSADT with no new metastases (P = .08). Mean PSA velocity increased by 3.0% for the placebo group and decreased by 3.4% for the celecoxib group (P = .02).

CONCLUSION: Although the primary efficacy objective was not met, this study provides some evidence for biologic activity of celecoxib in prostate cancer. Compared with placebo, celecoxib significantly decreased mean PSA velocity and tended to increase the proportion of men who doubled their PSADT.

Supported by Pfizer Inc.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. S. Antonarakis, E. I. Heath, J. R. Walczak, W. G. Nelson, H. Fedor, A. M. De Marzo, M. L. Zahurak, S. Piantadosi, A. J. Dannenberg, R. T. Gurganus, et al. Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers J. Clin. Oncol., October 20, 2009; 27(30): 4986 - 4993. [Abstract] [Full Text] [PDF]

				S. SRINIVAS and D. FELDMAN A Phase II Trial of Calcitriol and Naproxen in Recurrent Prostate Cancer Anticancer Res, September 1, 2009; 29(9): 3605 - 3610. [Abstract] [Full Text] [PDF]

				A. Fontana, L. Galli, A. Fioravanti, P. Orlandi, C. Galli, L. Landi, S. Bursi, G. Allegrini, E. Fontana, R. Di Marsico, et al. Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer Clin. Cancer Res., August 1, 2009; 15(15): 4954 - 4962. [Abstract] [Full Text] [PDF]

				S. J. Assinder, Q. Dong, H. Mangs, and D. R. Richardson Pharmacological Targeting of the Integrated Protein Kinase B, Phosphatase and Tensin Homolog Deleted on Chromosome 10, and Transforming Growth Factor-{beta} Pathways in Prostate Cancer Mol. Pharmacol., March 1, 2009; 75(3): 429 - 436. [Abstract] [Full Text] [PDF]

				O. W. Brawley, S. Lucia, and G. Andriole Chemoprevention of Prostate Cancer ASCO Educational Book, January 1, 2009; 2009(1): 62 - 64. [Abstract] [Full Text] [PDF]

				C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378. [Abstract] [Full Text] [PDF]

				F. Ponthan, M. Wickstrom, H. Gleissman, O. M. Fuskevag, L. Segerstrom, B. Sveinbjornsson, C. P.F. Redfern, S. Eksborg, P. Kogner, and J. I. Johnsen Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo Clin. Cancer Res., February 1, 2007; 13(3): 1036 - 1044. [Abstract] [Full Text] [PDF]

				S. Swami, A. V. Krishnan, J. Moreno, R. B. Bhattacharyya, D. M. Peehl, and D. Feldman Calcitriol and Genistein Actions to Inhibit the Prostaglandin Pathway: Potential Combination Therapy to Treat Prostate Cancer J. Nutr., January 1, 2007; 137(1): 205S - 210S. [Abstract] [Full Text] [PDF]

				J. Zhang, E. L. Ding, and Y. Song Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials JAMA, October 4, 2006; 296(13): 1619 - 1632. [Abstract] [Full Text] [PDF]

				R. N. DuBois Cyclooxygenase-2 Selective Inhibitors and Prostate Cancer: What Is the Clinical Benefit? J. Clin. Oncol., June 20, 2006; 24(18): 2691 - 2693. [Full Text] [PDF]